Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer

Clinical Cancer Research

Volumn 18, Issue 9, 2012, Pages 2613-2624

  Fijneman, Remond J A ^a   De Wit, Meike ^a   Pourghiasian, Maral ^a   Piersma, Sander R ^a   Pham, Thang V ^a   Warmoes, Marc O ^a   Lavaei, Mehrdad ^a   Piso, Chloe ^a   Smit, Fiona ^a   Delis van Diemen, Pien M ^a   Van Turenhout, Sietze T ^a   Terhaar Sive Droste, Jochim S ^a   Mulder, Chris J J ^a   Blankenstein, Marinus A ^a   Robanus Maandag, Els C ^b   Smits, Ron ^c   Fodde, Riccardo ^c   Van Hinsbergh, Victor W M ^a   Meijer, Gerrit A ^a   Jimenez, Connie R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; MESSENGER RNA; MINICHROMOSOME MAINTENANCE PROTEIN 4; ONCOPROTEIN; PROTEIN CHI3L1; PROTEIN S 100; PROTEIN S 100A9; PROTEOME; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SURVEILLANCE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

ADENOMA; ADIPOKINES; ANIMALS; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; COLON; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; LECTINS; MALE; MICE; MICE, INBRED C57BL; PRECANCEROUS CONDITIONS; PROTEOME; RECTUM; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84860522941     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1937     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Fodde R. The APC gene in colorectal cancer. Eur J Cancer 2002;38:867-71. (Pubitemid 34442313)
3. Toribara NW, Sleisenger MH. Screening for colorectal cancer. N Engl J Med 1995;332:861-7.
4. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005;5:199-209. (Pubitemid 40314951)
5. Huang CS, Lal SK, Farraye FA. Colorectal cancer screening in average risk individuals. Cancer Causes Control 2005;16:171-88. (Pubitemid 40685059)
6. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
7. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83. (Pubitemid 44215392)
8. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 2004;3:327-44. (Pubitemid 38702087)
9. Rajcevic U, Niclou SP, Jimenez CR. Proteomics strategies for target identification and biomarker discovery in cancer. Front Biosci 2009;14:3292-303.
10. Jimenez CR, Knol JC, Meijer GA, Fijneman RJ. Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics 2010;73:1873-95.
11. Jonkers J, Berns A. Conditional mouse models of sporadic cancer. Nat Rev Cancer 2002;2:251-65. (Pubitemid 37328779)
12. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008;5:e123.
13. Hung KE, Kho AT, Sarracino D, Richard LG, Krastins B, Forrester S, et al. Mass spectrometry-based study of the plasma proteome in a mouse intestinal tumor model. J Proteome Res 2006;5:1866-78.
14. Saam JR, Gordon JI. Inducible gene knockouts in the small intestinal and colonic epithelium. J Biol Chem 1999;274:38071-82. (Pubitemid 30026877)
15. Robanus-Maandag E, Koelink P, Breukel C, Salvatori D, Jagmohan-Changur S, Bosch C, et al. A new conditional Apc mutant mouse model for colorectal cancer. Carcinogenesis 2010;5:946-52.
16. Piersma SR, Fiedler U, Span S, Lingnau A, Pham TV, Hoffmann S, et al. Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res 2010;9:1913-22.
17. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002;74:5383-92. (Pubitemid 35215372)
18. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003;75:4646-58. (Pubitemid 37082259)
19. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005;4:1487-502. (Pubitemid 41555475)
20. Gao BB, Stuart L, Feener EP. Label-free quantitative analysis of one-dimensional PAGE LC/MS/MS proteome: application on angiotensin II-stimulated smooth muscle cells secretome. Mol Cell Proteomics 2008;7:2399-409.
21. Pham TV, Piersma SR, Warmoes M, Jimenez CR. Onthe beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. Bioinformatics 2010;26:363-9.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
23. Terhaar Sive Droste JS, Craanen ME, van der Hulst RW, Bartelsman JF, Bezemer DP, Cappendijk KR, et al. Colonoscopic yield of colorectal neoplasia in daily clinical practice. World J Gastroenterol 2009;15:1085-92.
24. Bendtsen JD, Jensen LJ, Blom N, Von Heijne G, Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel 2004;17:349-56. (Pubitemid 39093515)
25. Choi DS, Lee JM, Park GW, Lim HW, Bang JY, Kim YK, et al. Proteomic analysis of microvesicles derived from human colorectal cancer cells. J Proteome Res 2007;6:4646-55.
26. Davies RJ, Freeman A, Morris LS, BinghamS, Dilworth S, Scott I, et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002;359:1917-9. (Pubitemid 34615772)
27. Kim HJ, Kang HJ, Lee H, Lee ST, Yu MH, Kim H, et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res 2009;8:1368-79.
28. Yoo BC, Shin YK, Lim SB, Hong SH, Jeong SY, Park JG. Evaluation of calgranulin B in stools from the patients with colorectal cancer. Dis Colon Rectum 2008;51:1703-9.
29. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 2009;37:D885-90.
30. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007;5:1263-75.
31. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. Gene-Pattern 2.0. Nat Genet 2006;38:500-1.
32. Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82.
33. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194-202. (Pubitemid 43342164)
34. del Ara RM, Gonzalez-Polo RA, Caro A, del Amo E, Palomo L, Hernandez E, et al. Diagnostic performance of arginase activity in colorectal cancer. Clin Exp Med 2002;2:53-7. (Pubitemid 34743948)
35. Mielczarek M, Chrzanowska A, Scibior D, Skwarek A, Ashamiss F, Lewandowska K, et al. Arginase as a useful factor for the diagnosis of colorectal cancer liver metastases. Int J Biol Markers 2006;21:40-4.
36. Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJ, Ismail T. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 2007;97:971-7. (Pubitemid 47519304)
37. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008;205:2235-49.
38. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-49. (Pubitemid 39095585)
39. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. Ahuman protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005;4:1920-32. (Pubitemid 41830186)
40. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A 1995;92:7016-20.
41. Mlakar V, Berginc G, Volavsek M, Stor Z, Rems M, Glavac D. Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genesDCNandTPM1in colorectal cancer.BMC Cancer 2009;9:282.
42. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, et al. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 2009;58:79-89.
43. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10. (Pubitemid 46067310)
44. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009;27:844-50.
45. Willis ND, Cox TR, Rahman-Casans SF, Smits K, Przyborski SA, van den BP, et al. Lamin A/C is a risk biomarker in colorectal cancer. PLoS One 2008;3:e2988.
46. Belt EJ, Fijneman RJ, van den Berg EG, Bril H, Delis-van Diemen PM, TijssenM, et al. Loss of laminA/Cexpression in stage II and III colon cancer is associated with disease recurrence. Eur J Cancer 2011;47:1837-45.
47. Huang L, ShitashigeM, Satow R, Honda K, Ono M, Yun J, et al. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex. Gastroenterology 2007;133:1569-78. (Pubitemid 350029741)